CN112673017A - 可溶性多肽和使用其抑制白血病抑制因子活性的方法 - Google Patents

可溶性多肽和使用其抑制白血病抑制因子活性的方法 Download PDF

Info

Publication number
CN112673017A
CN112673017A CN201980058852.7A CN201980058852A CN112673017A CN 112673017 A CN112673017 A CN 112673017A CN 201980058852 A CN201980058852 A CN 201980058852A CN 112673017 A CN112673017 A CN 112673017A
Authority
CN
China
Prior art keywords
polypeptide
soluble
lifr
ser
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980058852.7A
Other languages
English (en)
Chinese (zh)
Inventor
S·A·亨特
J·R·科克伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CN112673017A publication Critical patent/CN112673017A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980058852.7A 2018-07-20 2019-07-19 可溶性多肽和使用其抑制白血病抑制因子活性的方法 Pending CN112673017A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862701399P 2018-07-20 2018-07-20
US62/701,399 2018-07-20
PCT/US2019/042648 WO2020018932A1 (en) 2018-07-20 2019-07-19 Soluble polypeptides and methods of using same for inhibiting leukemia inhibitory factor activity

Publications (1)

Publication Number Publication Date
CN112673017A true CN112673017A (zh) 2021-04-16

Family

ID=69164867

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980058852.7A Pending CN112673017A (zh) 2018-07-20 2019-07-19 可溶性多肽和使用其抑制白血病抑制因子活性的方法

Country Status (8)

Country Link
US (1) US12049490B2 (https=)
EP (1) EP3823983A4 (https=)
JP (2) JP7580800B2 (https=)
KR (1) KR102917499B1 (https=)
CN (1) CN112673017A (https=)
AU (1) AU2019305086B2 (https=)
CA (1) CA3106679A1 (https=)
WO (1) WO2020018932A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026006563A1 (en) * 2024-06-27 2026-01-02 Nvasc, Inc. Long-lasting lif proteins and formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010151A1 (en) * 1991-11-22 1993-05-27 Immunex Corporation Receptor for oncostatin m and leukemia inhibitory factor
WO2018029586A1 (en) * 2016-08-07 2018-02-15 Novartis Ag Mrna-mediated immunization methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2097291A1 (en) * 1990-12-13 1992-06-14 David P. Gearing Leukemia inhibitory factor receptors
CA2139504A1 (en) * 1992-07-01 1994-01-20 Nicos A. Nicola Leukaemia inhibitory factor-binding protein
AUPO632897A0 (en) * 1997-04-21 1997-05-15 Walter And Eliza Hall Institute Of Medical Research, The Novel chimeric molecules
EP1878745B1 (en) * 2005-04-22 2011-06-15 Keio University Humanin receptor or humanin-like polypeptide receptor
KR101235820B1 (ko) * 2012-02-17 2013-02-21 한국생명공학연구원 항암 표적치료제제 감수성 예측용 ｓｎｐ
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010151A1 (en) * 1991-11-22 1993-05-27 Immunex Corporation Receptor for oncostatin m and leukemia inhibitory factor
WO2018029586A1 (en) * 2016-08-07 2018-02-15 Novartis Ag Mrna-mediated immunization methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JULIETTE BITARD等: "Bitard and Juliette et al. and Mutations in the Immunoglobulin-like Domain of gp190, the Leukemia Inhibitory Factor (LIF) Receptor, Increase or DecreaseIts Affinity for LIF,", 《JOURNAL OF BIOLOGICAL CHEMISTRY》, vol. 278, no. 18, pages 16253 - 16261 *

Also Published As

Publication number Publication date
EP3823983A4 (en) 2022-05-18
EP3823983A1 (en) 2021-05-26
CA3106679A1 (en) 2020-01-23
AU2019305086B2 (en) 2024-11-28
KR20210032493A (ko) 2021-03-24
JP2021531002A (ja) 2021-11-18
US20210300992A1 (en) 2021-09-30
WO2020018932A1 (en) 2020-01-23
US12049490B2 (en) 2024-07-30
JP7580800B2 (ja) 2024-11-12
JP2024138287A (ja) 2024-10-08
AU2019305086A1 (en) 2021-02-18
KR102917499B1 (ko) 2026-01-26

Similar Documents

Publication Publication Date Title
US11028162B2 (en) Methods for manufacturing activatable binding polypeptides comprising matrix metalloprotease cleavable moieties
JP5368301B2 (ja) 可溶性ヘテロ二量体レセプター及びその使用
AU2016295024B2 (en) Her2 binding proteins based on di-ubiquitin muteins
JP7821741B2 (ja) 動物用のｉｌ４／ｉｌ１３受容体分子
JP2018505675A (ja) 新規なｅｇｆｒ結合タンパク質
EP4251130A1 (en) Compositions and methods for selective depletion of target molecules
WO2022032042A1 (en) Il12 receptor synthetic cytokines and methods of use
KR101243951B1 (ko) 가용성 종양 괴사 인자 수용체 돌연변이
WO2022032025A1 (en) Ifngr binding synthetic cytokines and methods of use
JP2024138287A (ja) 可溶性ポリペプチド、および白血病抑制因子の活性を阻害するためのその使用方法
JP2011501944A (ja) 改善された結合活性をもつ可溶性ｇｐ１３０変異蛋白質
KR102667654B1 (ko) 섬모 신경영양 인자 수용체 리간드-결합제 및 이의 사용 방법
US12122839B2 (en) IFNGR binding synthetic cytokines and methods of use
JP2002500011A (ja) Ｖ２０１ｄｎａ及びポリペプチド
US20230391891A1 (en) Il28a receptor binding synthetic cytokines and methods of use
EP3325514B1 (en) Her2 binding proteins based on di-ubiquitin muteins
TW202532437A (zh) Cfc1結合分子
JP2001526915A (ja) Ｖ１９６ｄｎａ及びポリペプチド
JP2002500012A (ja) Ｖ１９７ｄｎａ及びポリペプチド

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination